Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 May 10;6:25523. doi: 10.1038/srep25523

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2016, Macmillan Publishers Limited

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

Calculation of potentiation with the BRAID model for the combinations of veliparib and SN-38 in ES1 (a–c), olaparib and temozolomide in ES8 (d–f), and temozolomide and SN-38 in ES1 (g–i). (a,d,g) Best fit BRAID surface for each combination with estimated value of κ and confidence interval. (b,e,h) Estimated effect of the second drug in each combination in the presence of various levels of the first drug. Curve shifts to the left indicate potentiation. (c,f,i) EC₉₉ values of the second drug in each combination in the presence of various levels of the first drug. Note that though the combinations of veliparib vs SN-38 and olaparib vs. temozolomide exhibit similar κ values, olaparib produces considerably more potentiation of temozolomide than veliparib does of SN-38. This is due both to the increased potency of olaparib and the lower Hill slope of temozolomide.